Galectin Therapeutics (NASDAQ: GALT) is one of 188 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Galectin Therapeutics to similar companies based on the strength of its analyst recommendations, risk, dividends, valuation, profitability, earnings and institutional ownership.
This table compares Galectin Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Galectin Therapeutics Competitors||-3,262.61%||-524.52%||-39.32%|
This is a breakdown of recent ratings and recommmendations for Galectin Therapeutics and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Galectin Therapeutics Competitors||530||2432||6635||124||2.65|
Galectin Therapeutics currently has a consensus target price of $5.25, indicating a potential upside of 116.05%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.89%. Given Galectin Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Galectin Therapeutics is more favorable than its competitors.
Earnings and Valuation
This table compares Galectin Therapeutics and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Galectin Therapeutics||N/A||-$21.43 million||-4.42|
|Galectin Therapeutics Competitors||$217.29 million||-$39.39 million||-72.35|
Galectin Therapeutics’ competitors have higher revenue, but lower earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
Galectin Therapeutics has a beta of 2.56, suggesting that its share price is 156% more volatile than the S&P 500. Comparatively, Galectin Therapeutics’ competitors have a beta of 1.58, suggesting that their average share price is 58% more volatile than the S&P 500.
Insider & Institutional Ownership
11.1% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 49.8% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 38.8% of Galectin Therapeutics shares are owned by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Galectin Therapeutics beats its competitors on 7 of the 12 factors compared.
About Galectin Therapeutics
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company’s galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.
Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.